Abstracts

36 – Long-Acting Treatments for Tuberculosis

Long-acting injectable formulations are revolutionizing HIV treatment and prevention and have similar potential to improve the treatment and prevention of tuberculosis, including simpler, shorter regimens and expanded treatment options. This presentation will describe how long-acting injectable formulations could address important obstacles to ending the world’s oldest pandemic, review recent progress in the development of long-acting…

5 – Advances in CRISPR-Cas Editing Methods and Their Use in Virology and Immunology

Humanized mouse models, immunodeficient mice transplanted with human cells/tissues, have been used by HIV researchers for over 30 years to study aspects of HIV infection (e.g. transmission, pathogenesis, and persistence) and to perform efficacy testing of novel prevention, treatment, and cure approaches. This presentation will introduce the most commonly used humanized mouse models for HIV…

7 – Hepatitis B in the Gray Zone: Personalizing Treatment and Monitoring

Hepatitis B remains a significant cause of liver disease and remains the leading cause of hepatocellular carcinoma worldwide.  Effective therapy for hepatitis B is available, and nucleos(t)ide analogs (NAs) suppress hepatitis B DNA levels and normalize ALT levels. Long-term treatment can lead to reduction in necroinflammatory activity, with potential improvement in fibrosis or reduction in…

9 – Using Machine Learning to Focus HIV Prevention Interventions

This session explores the transformative impact of artificial intelligence (AI) across the HIV research continuum, from basic science to public health. Key highlights include AI’s role in accelerating drug discovery, optimizing clinical trials, and enhancing HIV care and prevention strategies. Emphasis is placed on ethical considerations, community engagement, and implementation science to ensure equitable and…

41 – Long COVID: Causes, Consequences, and the Way Forward

Long Covid is a disabling post-viral disease state that impacts over 400 million people worldwide, with no effective treatment currently available. Despite incomplete mechanistic understanding, lack of clinically actionable biomarkers, and insufficient policymaker recognition, significant progress has been made in recent years, revealing a clear histological and pathophysiological basis for the condition. SARS-CoV-2 infection prompts…

49 – Leveraging Private-Sector Pharmacies to Expand Reach of Biomedical HIV Prevention Interventions

Private-sector pharmacies are ubiquitous in many African countries yet underutilized for delivery of HIV prevention services, including pre- and post-exposure prophylaxis (PrEP and PEP). This is a missed opportunity, as pharmacies are staffed by medical professionals (e.g., pharmacists, pharmaceutical technologists); are frequently accessed for sexual and reproductive health products (e.g., contraception, treatment for sexually transmitted…